866-997-4948(US-Canada Toll Free)

Neuroprotection Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Published By :

Transparency Market Research

Published Date : Mar 2018

Category :

Pharmaceutical

No. of Pages : 197 Pages

Global Neuroprotection Market: Overview

This report on the Neuroprotection market analyzes the current and future scenario of the global market. Increasing incidence of neurological disorders. Product development, drug launches and initiatives for increasing awareness about Neuroprotection are the major drivers of the global Neuroprotection Market.

The Neuroprotection market report comprises an elaborate executive summary, which includes a market snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on product type, application, and geography. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis, by geography and market share analysis by key players, thus presenting a thorough analysis of the overall competitive scenario in the global Neuroprotection market.

Global Neuroprotection Market: Key Segments

Based on product type, the market has been segmented into Free Radical Trapping Agents (Antioxidants), Glutamate Antagonists (Anti-Excitotoxic Agents), Apoptosis Inhibitors, Anti-inflammatory Agents, Neurotrophic Factors (NTFs), Metal Ion Chelators, Stimulants, and Others. The application segments have been analyzed based on available approved products for prevention and treatment. The market size and forecast for each of these segments have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year.

Global Neuroprotection Market: Regional Outlook

Geographically, the global Neuroprotection market has been categorized into five major regions and the key countries in the respective region: North America (the U.S., Canada), Europe (the U.K., Germany, France, Spain, Italy, Russia, and Rest of Europe), Asia Pacific (India, China, Japan, Australia & New Zealand and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America) and Middle East & Africa (South Africa, GCC countries, Israel, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2015 to 2025, along with their respective CAGRs for the forecast period from 2017 to 2025, considering 2016 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in Report

The report also profiles major players in the global Neuroprotection market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. The major players in the Neuroprotection Market are, Daiichi Sankyo Company, Eli Lilly and Company, Allergan plc, Dr. Reddy’s Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca plc, Astrocyte Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Biogen Inc., and other prominent players.

 The global Neuroprotection market is segmented as given below:

  • Global Neuroprotection Market Revenue, by Product Type, 2015–2025
    • Free Radical Trapping Agents (Antioxidants)
    • Glutamate Antagonists (Anti-Excitotoxic Agents)
    • Apoptosis Inhibitors
    • Anti-inflammatory Agents
    • Neurotrophic Factors (NTFs)
    • Metal Ion Chelators
    • Stimulants
    • Others
  • Global Neuroprotection Market Revenue, By Application, 2015-2025
    • Prevention
    • Treatment
  • Global Neuroprotection Market Revenue, By Geography, 2015–2025
    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Spain
      • Italy
      • Russia
      • Rest of Europe
    • Asia Pacific
      • India
      • China
      • Japan
      • Australia & New Zealand
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
      • Rest of Latin America
    • Middle East & Africa
      • GCC countries
      • South Africa
      • Israel
      • Rest of Middle East & Africa

Table of Content

1. Preface 
1.1. Report Scope and Market Segmentation 
1.2. Research Highlights

2. Assumptions and Research Methodology 
2.1. Assumptions and Acronyms Used
2.2. Research Methodology

3. Executive Summary
3.1. Global Neuroprotection Market Size (US$ Mn) and Distribution, by Region, 2017 and 2025 
3.2. Global Neuroprotection Market: Market Snapshot

4. Market Overview
4.1. Global Neuroprotection Market: Product Overview 
4.2. Global Neuroprotection Market: Key Industry Developments

5. Market Dynamics
5.1. Drivers and Restraints Snapshot Analysis
5.2. Drivers
5.3. Restraints
5.4. Opportunities
5.5. Global Neuroprotection Market Outlook
5.6. Porters Five Forces
5.7. Pipeline Analysis
5.8. Mergers & Acquisition
5.9. Product mapping

6. Global Neuroprotection Market Analysis, by Product
6.1. Introduction
6.2. Key Insights
6.3. Global Neuroprotection Market Value Share Analysis, by Product
6.4. Global Neuroprotection Market Value (US$ Mn) Forecast , by Product
6.4.1. Free Radical Trapping Agents (Antioxidants)
6.4.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
6.4.3. Apoptosis Inhibitors
6.4.4. Anti-inflammatory Agents
6.4.5. Neurotrophic Factors (NTFs)
6.4.6. Metal Ion Chelators
6.4.7. Stimulants
6.4.8. Others
6.5. Global Neuroprotection Market Attractiveness, by Product

7. Global Neuroprotection Market, By Application
7.1.  Global Neuroprotection Market Value Share Analysis, by Application
7.2. Global Neuroprotection Market Value (US$ Mn) Forecast, by Application
7.2.1. Prevention
7.2.2. Treatment
7.3. Global Neuroprotection Market Attractiveness Analysis, by Application
7.3.1. Prevention
7.3.2. Treatment

8. Global Neuroprotection Market Analysis, by Region
8.1. Global Neuroprotection Market Forecast, by Region, 2015–2025 
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Neuroprotection Market Value Share Analysis, by Region
8.3. Global Neuroprotection Market Attractiveness Analysis, by Region

9. North America Neuroprotection Market Analysis
9.1. North America Neuroprotection Market Key Findings
9.2. North America Neuroprotection Market Overview
9.3. North America Neuroprotection Market Value Share Analysis, by Product
9.3.1. Free Radical Trapping Agents (Antioxidants)
9.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
9.3.3. Apoptosis Inhibitors
9.3.4. Anti-inflammatory Agents
9.3.5. Neurotrophic Factors (NTFs)
9.3.6. Metal Ion Chelators
9.3.7. Stimulants
9.3.8. Others
9.4. North America Neuroprotection Market Value Share Analysis, by Application
9.4.1. Prevention
9.4.2. Treatment
9.5. North America Neuroprotection Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Neuroprotection Market Attractiveness Analysis
9.6.1. By Product
9.6.2. By Application
9.6.3. By Country
9.7. Trends

10. Europe Neuroprotection Market Analysis
10.1. Europe Neuroprotection Market Key Findings
10.2. Europe Neuroprotection Market Overview
10.3. Europe Neuroprotection Market Value Share Analysis, by Product
10.3.1. Free Radical Trapping Agents (Antioxidants)
10.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
10.3.3. Apoptosis Inhibitors
10.3.4. Anti-inflammatory Agents
10.3.5. Neurotrophic Factors (NTFs)
10.3.6. Metal Ion Chelators
10.3.7. Stimulants
10.3.8. Others
10.4. Europe Neuroprotection Market Value Share Analysis, by Application
10.4.1. Prevention
10.4.2. Treatment
10.5. Europe Neuroprotection Market Forecast, by Country
10.5.1. Germany
10.5.2. U.K.
10.5.3. France
10.5.4. Italy
10.5.5. Spain
10.5.6. Russia
10.5.7. Rest of Europe
10.6. Europe Neuroprotection Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Application
10.6.3. By Country
10.7. Trends

11. Asia Pacific Neuroprotection Market Analysis
11.1. Asia Pacific Neuroprotection Market Key Findings
11.2. Asia Pacific Neuroprotection Market Overview
11.3. Asia Pacific Neuroprotection Market Value Share Analysis, by Product
11.3.1. Free Radical Trapping Agents (Antioxidants)
11.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
11.3.3. Apoptosis Inhibitors
11.3.4. Anti-inflammatory Agents
11.3.5. Neurotrophic Factors (NTFs)
11.3.6. Metal Ion Chelators
11.3.7. Stimulants
11.3.8. Others
11.4. Asia Pacific Neuroprotection Market Value Share Analysis, by Application
11.4.1. Prevention
11.4.2. Treatment
11.5. Asia Pacific Neuroprotection Market Forecast, by Country
11.5.1. China 
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.6. Asia Pacific Neuroprotection Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Application
11.6.3. By Country
11.7. Trends

12. Latin America Neuroprotection Market Analysis
12.1. Latin America Neuroprotection Market Key Findings
12.2. Latin America Neuroprotection Market Overview
12.3. Latin America Neuroprotection Market Value Share Analysis, by Product
12.3.1. Free Radical Trapping Agents (Antioxidants)
12.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
12.3.3. Apoptosis Inhibitors
12.3.4. Anti-inflammatory Agents
12.3.5. Neurotrophic Factors (NTFs)
12.3.6. Metal Ion Chelators
12.3.7. Stimulants
12.3.8. Others
12.4. Latin America Neuroprotection Market Value Share Analysis, by Application
12.4.1. Prevention
12.4.2. Treatment
12.5. Latin America Neuroprotection Market Forecast, by Country
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of LATAM
12.6. Latin America Neuroprotection Market Attractiveness Analysis
12.6.1. By Product
12.6.2. By Application
12.6.3. By Country
12.7. Trends

13. MEA Neuroprotection Market Analysis
13.1. MEA Neuroprotection Market Key Findings
13.2. MEA Neuroprotection Market Overview
13.3. MEA Neuroprotection Market Value Share Analysis, by Product
13.3.1. Free Radical Trapping Agents (Antioxidants)
13.3.2. Glutamate Antagonists (Anti-Excitotoxic Agents)
13.3.3. Apoptosis Inhibitors
13.3.4. Anti-inflammatory Agents
13.3.5. Neurotrophic Factors (NTFs)
13.3.6. Metal Ion Chelators
13.3.7. Stimulants
13.3.8. Others
13.4. MEA Neuroprotection Market Value Share Analysis, by Application
13.4.1. Prevention
13.4.2. Treatment
13.5. MEA Neuroprotection Market Forecast, by Country
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Israel
13.5.4. Rest of MEA
13.6. North America Neuroprotection Market Attractiveness Analysis
13.6.1. By Product
13.6.2. By Application
13.6.3. By Country
13.7. Trends

14. Competition Landscape
14.1. Global Neuroprotection Market Share Analysis, by Company (2016)
14.2. Company Profiles
14.2.1. Daiichi Sankyo Company  
14.2.1.1. Overview (HQ, Employee Strength, Business Segments)
14.2.1.2. Financials
14.2.1.3. Recent Developments
14.2.1.4. Strategy
14.2.2. Eli Lilly and Company  
14.2.2.1. Overview (HQ, Employee Strength, Business Segments)
14.2.2.2. Financials
14.2.2.3. Recent Developments
14.2.2.4. Strategy
14.2.3. Allergan plc.
14.2.3.1. Overview (HQ, Employee Strength, Business Segments)
14.2.3.2. Financials
14.2.3.3. Recent Developments
14.2.3.4. Strategy
14.2.4. Dr. Reddy’s Laboratories Ltd.
14.2.4.1. Overview (HQ, Employee Strength, Business Segments)
14.2.4.2. Financials
14.2.4.3. Recent Developments
14.2.4.4. Strategy
14.2.5. Teva Pharmaceutical Industries Ltd. 
14.2.5.1. Overview (HQ, Employee Strength, Business Segments)
14.2.5.2. Financials
14.2.5.3. Recent Developments
14.2.5.4. Strategy
14.2.6. Novartis AG  
14.2.6.1. Overview (HQ, Employee Strength, Business Segments)
14.2.6.2. Financials
14.2.6.3. Recent Developments
14.2.6.4. Strategy
14.2.7. AstraZeneca plc.
14.2.7.1. Overview (HQ, Employee Strength, Business Segments)
14.2.7.2. Financials
14.2.7.3. Recent Developments
14.2.7.4. Strategy
14.2.8. AstraZeneca plc.
14.2.8.1. Overview (HQ, Employee Strength, Business Segments)
14.2.8.2. Financials
14.2.8.3. Recent Developments
14.2.8.4. Strategy
14.2.9. Astrocyte Pharmaceuticals, Inc.
14.2.9.1. Overview (HQ, Employee Strength, Business Segments)
14.2.9.2. Financials
14.2.9.3. Recent Developments
14.2.9.4. Strategy
14.2.10. F. Hoffmann-La Roche AG
14.2.10.1. Overview (HQ, Employee Strength, Business Segments)
14.2.10.2. Financials
14.2.10.3. Recent Developments
14.2.10.4. Strategy
14.2.11. Biogen Inc.
14.2.11.1. Overview (HQ, Employee Strength, Business Segments)
14.2.11.2. Financials
14.2.11.3. Recent Developments
14.2.11.4. Strategy

List of Table

Table 01: Neuroprotection Market: Pipeline Analysis
Table 02: Neuroprotection Market: Pipeline Analysis
Table 03: Neuroprotection Market: Pipeline Analysis
Table 04: Neuroprotection Market Product mapping
Table 05: Neuroprotection Market Product mapping
Table 06: Neuroprotection Market Mergers & Acquisitions
Table 07: Global Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 08: Global Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 09: Global Neuroprotection Market Size (US$ Mn) Forecast, by Region, 2015–2025
Table 10: North America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 11: North America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 12: North America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 13: Europe Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 14: Europe Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 15: Europe Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 16: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 17: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 18: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 19: Latin America Neuroprotection Market Size (US$ Mn) and Forecast, by Country, 2015–2025
Table 20: Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 21: Latin America Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025
Table 22: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
Table 23: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Product, 2015–2025
Table 24: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, by Application, 2015–2025

List of Chart

Figure 01: Global Neuroprotection Market Revenue Projections (US$ Mn), 2015–2025
Figure 02: Global Neuroprotection Market Value Share Analysis, Product, 2016 and 2025
Figure 03: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Free Radical Trapping Agents (Antioxidants), 2015-2025
Figure 04: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Glutamate Antagonists, 2015-2025
Figure 05: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Apoptosis Inhibitors, 2015-2025
Figure 06: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Anti-inflammatory Agents, 2015-2025
Figure 07: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Neurotrophic Factors (NTFs), 2015-2025
Figure 08: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Metal Ion Chelators, 2015-2025
Figure 09: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Stimulants, 2015-2025
Figure 10: Global Neuroprotection Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2015-2025
Figure 11: Global Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 12: Global Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 13: Global Neuroprotection Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Prevention, 2015–2025
Figure 14: Global Neuroprotection Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Treatment, 2015–2025
Figure 15: Global Neuroprotection Market Attractiveness Analysis, by Application, 2017–2025
Figure 16: Global Neuroprotection Market Value Share Analysis, by Region, 2016 and 2025
Figure 17: Global Neuroprotection Market Attractiveness Analysis, by Region, 2017–2025
Figure 18: North America Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 19: North America Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
Figure 20: North America Neuroprotection Market Attractiveness Analysis, by Country
Figure 21: North America Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
Figure 22: North America Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
Figure 23: North America Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 24: North America Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 25: North America Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
Figure 26: Europe Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 27: Europe Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
Figure 28: Europe Neuroprotection Market Attractiveness Analysis, by Country
Figure 29: Europe Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
Figure 30: Europe Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
Figure 31: Europe Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 32: Europe Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 33: Europe Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
Figure 34: Asia Pacific Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 35: Asia Pacific Neuroprotection Market Y-o-Y Growth Projection, 2016–2025
Figure 36: Asia Pacific Neuroprotection Market Attractiveness, by Country/Sub-region
Figure 37: Asia Pacific Neuroprotection Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 38: Asia Pacific Neuroprotection Market Value Share, by Product, 2016 and 2025
Figure 39: Asia Pacific Neuroprotection Market Attractiveness, by Product, 2017–2025
Figure 40: Asia Pacific Neuroprotection Market Value Share, by Application, 2016 and 2025
Figure 41: Asia Pacific Neuroprotection Market Attractiveness, by Application, 2017–2025
Figure 42: Latin America Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 43: Latin America Neuroprotection Market Size, Y-o-Y Growth Projection, 2016–2025
Figure 44: Latin America Neuroprotection Market Attractiveness Analysis, by Country
Figure 45: Latin America Neuroprotection Market Value Share Analysis, by Country, 2016 and 2025
Figure 46: Latin America Neuroprotection Market Value Share Analysis, by Product, 2016 and 2025
Figure 47: Latin America Neuroprotection Market Attractiveness Analysis, by Product, 2017–2025
Figure 48: Latin America Neuroprotection Market Value Share Analysis, by Application, 2016 and 2025
Figure 49: Latin America Neuroprotection Market Attractiveness Analysis, by Application, 2017-2025
Figure 50: Middle East & Africa Neuroprotection Market Size (US$ Mn) Forecast, 2015–2025
Figure 51: Middle East & Africa Neuroprotection Market Y-o-Y Growth Projection, 2016–2025
Figure 52: Middle East & Africa Neuroprotection Market Attractiveness, by Country/Sub-region
Figure 53: Middle East & Africa Neuroprotection Market Value Share, by Country/Sub-region, 2016 and 2025
Figure 54: Middle East & Africa Neuroprotection Market Value Share, by Product, 2016 and 2025
Figure 55: Middle East & Africa Neuroprotection Market Attractiveness, by Product, 2017–2025
Figure 56: Middle East & Africa Neuroprotection Market Value Share, by Application, 2016 and 2025
Figure 57: Middle East & Africa Neuroprotection Market Attractiveness, by Application, 2017–2025
Figure 58: Global Neuroprotection Market, Company Share, 2016
Figure 59: DAIICHI SANKYO COMPANY, LIMITED R&D Intensity (%) 2015–2016
Figure 60: DAIICHI SANKYO COMPANY, LIMITED Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 61: DAIICHI SANKYO COMPANY, LIMITED Breakdown of Net Sales, By Region, 2016
Figure 62: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 63: Eli Lilly and Company R&D Intensity and Sales – Company Level, 2015–2016
Figure 64: Eli Lilly and Company Breakdown of Net Sales, By Region, 2016
Figure 65: Eli Lilly and Company Breakdown of Net Sales, by Neuroscience products sales, 2016
Figure 66: Allergan plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 67: Allergan plc. R&D Intensity and Sales & Marketing Intensity – Company Level, 2015–2016
Figure 68: Allergan plc. Breakdown of Net Sales, by Business Segment, 2016
Figure 69: Allergan plc. Breakdown of Net Sales, by Central Nervous Products Sale, 2016
Figure 70: Dr. Reddy’s Laboratories Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014–2017
Figure 71: Dr. Reddy’s Laboratories Ltd. R&D Intensity and Sales & Marketing Intensity US$ Mn – Company Level or Segment Level, 2016–2017
Figure 72: Dr. Reddy’s Laboratories Ltd. Breakdown of Net Sales, by Region, 2017
Figure 73: Dr. Reddy’s Laboratories Ltd. Breakdown of Net Sales, by Business Segments, 2017
Figure 74: Teva Pharmaceutical Industries Ltd. Revenue (US$ Mn) & Y-o-Y Growth (%), 2013–2016
Figure 75: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) – Company Level, 2015–2016
Figure 76: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2016
Figure 77: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2016
Figure 78: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013–2016
Figure 79: Novartis AG Marketing & Sales, and R&D Expenses, 2015–2016
Figure 80: Novartis AG Breakdown of Net Sales, by Business Segment, 2016
Figure 81: Novartis AG Breakdown of Net Sales, by Region, 2016
Figure 82: AstraZeneca plc. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013–2016
Figure 83: Astra Zeneca R&D Intensity (%) 2015–2016
Figure 84: AstraZeneca plc. Breakdown of Net Sales, by Region (Company Level), 2016
Figure 85: AstraZeneca plc. Breakdown of Net Sales, by Therapy areas 2016
Figure 86: F. Hoffmann-La Roche AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 87: F. Hoffmann-La Roche AG Marketing and R&D Expenses, 2015–2016
Figure 88: F. Hoffmann-La Roche AG Breakdown of Net Sales, by Business Division, 2016
Figure 89: F. Hoffmann-La Roche AG Breakdown of Net Sales (Pharmaceutical Segment), by Region,  2016
Figure 90: Biogen Revenue (US$ Bn) and Y-o-Y Growth (%), 2013–2016
Figure 91: Biogen R&D Intensity (%), 2015–2016
Figure 92: Biogen Breakdown of Net Sales, by Region, 2016
Figure 93: Biogen Breakdown of Net Sales, by Product, 2016

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *